NDLI: Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.

Please wait, while we are loading the content...

Year: 2017 Volume: 97

Year: 2016 Volume: 96

Year: 2016 Volume: 95

Year: 2016 Volume: 94

Year: 2015 Volume: 93

Year: 2015 Volume: 92

Year: 2015 Volume: 91

Year: 2014 Volume: 90

Year: 2014 Volume: 89

Year: 2014 Volume: 88

Year: 2013 Volume: 87

Year: 2013 Volume: 86

Year: 2013 Volume: 85

Year: 2012 Volume: 84

Year: 2012 Volume: 83

Year: 2012 Volume: 82

Year: 2011 Volume: 81

Year: 2011 Volume: 80

Year: 2011 Volume: 79

Year: 2010 Volume: 78

Year: 2010 Volume: 77

Year: 2010 Volume: 76

Year: 2010 Volume: 76 Issue: 5

Year: 2010 Volume: 76 Issue: 4

Year: 2010 Volume: 76 Issue: 3

Year: 2010 Volume: 76 Issue: 3 Supplementary

Year: 2010 Volume: 76 Issue: 2

Year: 2010 Volume: 76 Issue: 1

Is radiotherapy a good adjuvant strategy for men with a history of cryptorchism and stage I seminoma?

Estimating need for palliative external beam radiotherapy in adult cancer patients.

Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.

Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.

A prognostic index for predicting lymph node metastasis in minor salivary gland cancer.

Physician expectations of treatment outcomes for patients with brain metastases referred for whole brain radiotherapy.

Margin on gross tumor volume and risk of local recurrence in head-and-neck cancer.

Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas.

The lateral decubitus breast boost: description, rationale, and efficacy.

Intraoperative spillage of favorable histology wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group.

Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.

Comparison between hybrid direct aperture optimized intensity-modulated radiotherapy and forward planning intensity-modulated radiotherapy for whole breast irradiation.

Time of decline in sexual function after external beam radiotherapy for prostate cancer.

Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.

Radiation therapy alone for imaging-defined meningiomas.

Regional lung density changes after radiation therapy for tumors in and around thorax.

Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.

Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation.

Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer.

Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy.

Selective nodal irradiation for head and neck cancer using intensity-modulated radiotherapy: application of RTOG consensus guidelines in routine clinical practice.

Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.

Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

Differences in clinical results after LINAC-based single-dose radiosurgery versus fractionated stereotactic radiotherapy for patients with vestibular schwannomas.

Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy.

Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society.

Prognosis for mammographically occult, early-stage breast cancer patients treated with breast-conservation therapy.

Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma.

Comparison of respiratory-gated and respiratory-ungated planning in scattered carbon ion beam treatment of the pancreas using four-dimensional computed tomography.

Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes.

Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.

Feasibility of single-isocenter volumetric modulated arc radiosurgery for treatment of multiple brain metastases.

Hypofractionation: what does it mean for prostate cancer treatment?

Quality measures, standards, and accreditation for breast centers in the United States.

Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras.

Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer.

Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.

Distinct signaling pathways after higher or lower doses of radiation in three closely related human lymphoblast cell lines.

Role of intercellular adhesion molecule-1 in radiation-induced brain injury.

Irradiation with carbon ion beams induces apoptosis, autophagy, and cellular senescence in a human glioma-derived cell line.

A murine model for the study of molecular pathogenesis of radiation proctitis.

Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models.

The development and clinical use of a beam ON-LINE PET system mounted on a rotating gantry port in proton therapy.

Response to 'Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center experience' (Int J Radiat Oncol Biol Phys 2009;73:795-801).

Clinical experience with image-guided radiotherapy in an accelerated partial breast intensity-modulated radiotherapy protocol: in regard to Leonard CE et al. (Int J Radiat Oncol Biol Phys Epub May 19, 2009).

Year: 2009 Volume: 75

Year: 2009 Volume: 74

Year: 2009 Volume: 73

Year: 2008 Volume: 72

Year: 2008 Volume: 71

Year: 2008 Volume: 70

Year: 2007 Volume: 69

Year: 2007 Volume: 68

Year: 2007 Volume: 67

Year: 2006 Volume: 66

Year: 2006 Volume: 65

Year: 2006 Volume: 64

Year: 2005 Volume: 63

Year: 2004 Volume: 59

Year: 1976 Volume: 1

Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Henry, Ann M. Al-Qaisieh, Bashar Gould, Kathy Bownes, Peter Smith, Jonathan Carey, Brendan Bottomley, David Ash, Dan
Description	Country affiliation: United kingdom Author Affiliation: Henry AM ( Department of Clinical Oncology, St. James's Institute of Oncology, St. James's University Hospital, Leeds, United Kingdom. Ann.Henry@leedsth.nhs.uk)
Abstract	PURPOSE: This study reports the 10-year experience of permanent brachytherapy monotherapy at a single UK center. METHODS AND MATERIALS: Between March 1995 and September 2004, 1,298 patients underwent trans-rectal ultrasound (TRUS) planned transperineal brachytherapy delivering 145 Gy using I-125. No patient received supplemental external beam; 44.2% received neoadjuvant hormones. In 688, CT postimplant dosimetry was available. Outcome data were analyzed in terms of overall survival (OS), disease specific survival (DSS), and PSA relapse-free survival (PSA-RFS). RESULTS: The mean age was 62.9 (range, 34-83) years. Median follow-up was 4.9 years (range, 2.03-11.7 years). OS and DSS were 85% and 95%, respectively, at 10 years. Twenty-one patients died from prostate cancer (1.6%) and 34 (2.5%) from unrelated causes. Seventy-four (5.7%) developed evidence of clinical failure. Overall PSA-RFS was 79.9% and 72.1% at 10 years (American Society for Therapeutic Radiology and Oncology [ASTRO] and Nadir+2 definitions, respectively). Higher presenting PSA or Gleason score and use of neoadjuvant hormones were associated with an increased risk of biochemical failure (p <0.01). Biochemical control was achieved in 86.4%, 76.7%, and 60.6% (ASTRO) and 72.3%, 73.5%, and 57.6% (Nadir+2) of patients in low-, intermediate-, and high-risk groups, respectively. Biochemical control was achieved in 88% of patients with D(90) > or =140 Gy and in 78% of patients with D(90) <140 Gy (p <0.01). CONCLUSIONS: I-125 brachytherapy alone achieved excellent rates of medium-term biochemical control in both low- and selected intermediate-risk localized prostate cancer patients. Postimplant dosimetry improved with experience and longer follow-up, confirming the relationship of D(90) with biochemical control.
File Format	HTM / HTML
ISSN	03603016
Issue Number	1
Volume Number	76
e-ISSN	1879355X
Journal	International Journal of Radiation OncologyastBiologyastPhysics
Language	English
Publisher	Elsevier
Publisher Date	2010-01-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Radiology Brachytherapy Methods Iodine Radioisotopes Therapeutic Use Prostatic Neoplasms Radiotherapy Adult Aged Aged, 80 And Over Androgen Antagonists Cause Of Death Disease-free Survival Follow-up Studies Humans Male Middle Aged Proportional Hazards Models Prostate-specific Antigen Blood Mortality Pathology Radiotherapy Dosage Reference Values Treatment Outcome Ultrasonography, Interventional Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Radiology, Nuclear Medicine and Imaging Cancer Research Radiation Oncology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in